AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec. “We are pleased to regain rights for AV-203 as we believe in the potential of this innovative therapy and are looking forward to maximizing its value,” said Michael Bailey, chief business officer, AVEO Oncology. “As stated in our recently outlined strategy, this amended agreement enables us to seek a partner with established oncology capabilities that can accelerate and financially support the clinical development of AV-203.” AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares after opening at $1.55 on last trade day and at the end of the day closed at $1.51. Company price to sales ratio in past twelve months was calculated as 59.88 and price to cash ratio as 0.66. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) showed a negative weekly performance of -15.64%.
Charles & Colvard, Ltd. (NASDAQ:CTHR), the sole source of created moissanite and Forever Brilliant®, The World’s Most Brilliant Gem®, reports sales for the three and 12 months ended December 31, 2013 increased 6% and 27%, respectively, over the prior-year periods. Fourth quarter 2013 sales were the strongest since the fourth quarter of 2006; sales improved 6% to $8.6 million vs. $8.1 million in the fourth quarter 2012, with increases driven by sales of loose jewels including the Company’s whiter Forever Brilliant® moissanite. Charles & Colvard, Ltd. (NASDAQ:CTHR) shares fell -6.98% in last trading session and ended the day on $2.93. CTHR return on equity ratio is recorded as 4.70% and its return on assets is 4.40%. Charles & Colvard, Ltd. (NASDAQ:CTHR) yearly performance is -24.09%.
Onconova Therapeutics Inc (NASDAQ:ONTX) provided a corporate update and reported financial results for its year ended December 31, 2013. Onconova Therapeutics Inc (NASDAQ:ONTX) shares moved down -5.12% in last trading session and was closed at $6.30, while trading in range of $6.05 – $6.70. Onconova Therapeutics Inc (NASDAQ:ONTX) year to date (YTD) performance is -45.12%.
BioTime, Inc. (NYSEMKT:BTX), reported financial results for the fourth quarter and year ended December 31, 2013 and highlighted its fourth quarter and recent corporate accomplishments. BioTime’s subsidiary Asterias Biotherapeutics, Inc. completed the acquisition of stem cell assets from Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine. BioTime conducted a clinical safety study of Renevia™, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, at The Stem Center in Palma de Mallorca, Spain. Examinations of the subjects after they received Renevia™ injections showed that Renevia™ was well tolerated by all subjects with no serious adverse events or subject withdrawals. BioTime, Inc. (NYSEMKT:BTX) weekly performance is -11.65%. On last trading day company shares ended up $3.11. BioTime, Inc. (NYSEMKT:BTX) distance from 50-day simple moving average (SMA50) is -14.58%.
Leave a Reply